These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 22732527)

  • 1. Safety profile of RNAi nanomedicines.
    Barros SA; Gollob JA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi nanomedicines: challenges and opportunities within the immune system.
    Weinstein S; Peer D
    Nanotechnology; 2010 Jun; 21(23):232001. PubMed ID: 20463388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
    Tabernero J; Shapiro GI; LoRusso PM; Cervantes A; Schwartz GK; Weiss GJ; Paz-Ares L; Cho DC; Infante JR; Alsina M; Gounder MM; Falzone R; Harrop J; White AC; Toudjarska I; Bumcrot D; Meyers RE; Hinkle G; Svrzikapa N; Hutabarat RM; Clausen VA; Cehelsky J; Nochur SV; Gamba-Vitalo C; Vaishnaw AK; Sah DW; Gollob JA; Burris HA
    Cancer Discov; 2013 Apr; 3(4):406-17. PubMed ID: 23358650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of RNAi therapeutics: work in progress.
    Miller AD
    Expert Rev Med Devices; 2013 Nov; 10(6):781-811. PubMed ID: 24195461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi-based nanomedicines for targeted personalized therapy.
    Daka A; Peer D
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1508-21. PubMed ID: 22975009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grand challenges in modulating the immune response with RNAi nanomedicines.
    Goldsmith M; Mizrahy S; Peer D
    Nanomedicine (Lond); 2011 Dec; 6(10):1771-85. PubMed ID: 22122585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based nanoparticles in the systemic delivery of siRNA.
    Lin Q; Chen J; Zhang Z; Zheng G
    Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo delivery of RNAi with lipid-based nanoparticles.
    Huang L; Liu Y
    Annu Rev Biomed Eng; 2011 Aug; 13():507-30. PubMed ID: 21639780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions.
    Ballarín-González B; Howard KA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1717-29. PubMed ID: 22800620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
    Eifler AC; Thaxton CS
    Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
    Meade BR; Dowdy SF
    Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
    Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
    Zhou Y; Zhang C; Liang W
    J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry and formulations for siRNA therapeutics.
    Gallas A; Alexander C; Davies MC; Puri S; Allen S
    Chem Soc Rev; 2013 Oct; 42(20):7983-97. PubMed ID: 23857524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicinal delivery approaches for therapeutic siRNA.
    Keller M
    Int J Pharm; 2009 Sep; 379(2):210-1. PubMed ID: 19716034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses.
    DeVincenzo JP
    Antivir Ther; 2012; 17(1 Pt B):213-25. PubMed ID: 22311654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.